BioSpace News Archive

Genetown

Inconsistent Results in Subtype Trip Up Dicerna with Rare Disease Drug

While the study hit its primary efficacy endpoints, investors are likely concerned about reports of “inconsistent results” regarding reducing Uox excretion in a subtype of patients with the rare disease.

August 6, 2021
·
2 min read
·
Alex Keown
Policy

With US Covered, Novavax Moves COVID-19 Vaccine Focus to Rest of World

U.S. authorization is likely not a priority for Novavax since half the population is already vaccinated. But with other parts of the world, there’s still plenty of room for a Novavax vaccine.

August 6, 2021
·
3 min read
·
Mark Terry
Drug Development

Aprea’s “Cancer Guardian” Protein Activator Drug Forced to Press Pause

Aprea faces another disappointment this week in the clinic. The FDA held up a yellow card, and the Boston-based biotech has placed a partial clinical hold on its myeloid malignancy program.

August 6, 2021
·
1 min read
·
Kate Goodwin
Drug Development

Clinical Catch-Up: August 2-6

It was a busy week for clinical trial announcements. Take a look.

August 6, 2021
·
7 min read
·
Mark Terry
Business

Oyster Point Pharma Inks Deal with Ji Xing for Dry Eye Disease Therapies

Oyster Point Pharma inked a license and collaboration deal with Ji Xing Pharmaceuticals to develop and market OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays for dry eye disease in Great China.

August 6, 2021
·
3 min read
·
Mark Terry
Drug Development

Genetown’s EQRx Joins SPAC Parade, Debuts on Nasdaq

The deal will give EQRx a pre-transaction enterprise value of $3.65 billion and an immediate $1.8 billion in cash that will be used to advance the development of the company’s pipeline.

August 6, 2021
·
2 min read
·
Alex Keown
Business

BioSpace Movers & Shakers, Aug. 6

Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers.

August 6, 2021
·
5 min read
·
Alex Keown
Drug Development

South African Trial Supports J&J’s COVID-19 Vaccine Against Circulating Delta Strain

The co-head of a Phase III trial reported Johnson & Johnson’s single-shot COVID-19 vaccine was highly effective at preventing severe disease, including among patients infected with the circulating Delta coronavirus variant.

August 6, 2021
·
3 min read
·
Brandon May
Business

Sierra Signs Exclusive Deal with AstraZeneca for Potent BRD4 BET Inhibitor

Sierra will have access to AZD5153, a potent and selective BRD4 BET inhibitor, to initiate a study that combines the said component with momelotinib for treating patients with myelofibrosis.

August 6, 2021
·
2 min read
·
Vanessa Doctor, RN
FDA

FDA Action Alert: Medexus and Jazz

Although August is a fairly busy month for PDUFA dates, there were only two on the U.S. FDA’s calendar for this week, and one of those has already been reported. Here’s a look.

August 6, 2021
·
3 min read
·
Mark Terry